

Data Sharing Statement

Normark J, Vikström L, Gwon Y-D, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. *N Engl J Med*. DOI: 10.1056/NEJMc2110716.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Data that are attached to primary objective of clinical trial (EudraCT 2021-000683-30) will be shared latest 1 year after completion of the trial. These include individual participant data that underlie the results reported in this article, after de-identification. Study protocols and statistical analysis plan with relation to this study are available at request and has been shared with the New England Journal of Medicine.
Additional information about data	—
How or where can the data be obtained?	Enquires should be directed to clas.ahlm@umu.se.
When will data availability begin?	—
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	Data can only be shared to investigators whose proposed use of the data has been approved by an independent ethical review committee identified for this purpose, and in accordance with Swedish law and GDPR.
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on July 14, 2021, at NEJM.org.